-- 原油価格は木曜日に上昇し、4年ぶりの高値をつけた。中東情勢の悪化と、同地域における供給途絶の長期化への懸念が背景にある。 ブレント原油は直近で2.9%上昇し1バレル＝121.48ドル、ウエスト・テキサス・インターミディエイト（WTI）原油は1.5%上昇し1バレル＝108.51ドルとなった。ロイター通信は木曜日の報道で、匿名の情報源を引用したAxiosの報道を受け、ドナルド・トランプ米大統領がイラン核開発計画に関する交渉再開を促すため、イランへの一連の軍事攻撃計画について説明を受ける予定だと伝えた。 さらにロイター通信はホワイトハウス関係者の話として、トランプ大統領が石油会社と、数カ月に及ぶ可能性のある米国の封鎖措置の影響を軽減する方法について協議したと報じた。 ロイター通信は、価格高騰が続けば、世界的なインフレの再燃と燃料価格の上昇を招く恐れがあると指摘した。 「ブレント原油価格が1バレル150ドルに達する可能性がないと考えている人は、今すぐ目をそらした方がいいでしょう」と、ロイター通信は石油ブローカーPVMのジョン・エバンス氏の発言を引用して報じた。 「イラン紛争の短期的な解決やホルムズ海峡の再開の見通しは依然として暗い」と、IGマーケットのアナリスト、トニー・シカモア氏はメモの中で述べている。
Related Articles
Research
Research Alert: Xpo Q1 Earnings Beat As Margins Expand And Tonnage Turns Positive
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:XPO reported Q1 EPS of $1.01 vs. $0.73 a year ago, beating consensus by $0.13, while revenue of $2.1B grew 7% and beat estimates by $60M. Adjusted EBITDA surged 15% to $319M, demonstrating accelerating momentum across the business. We believe the combination of margin expansion, positive volume inflection, and strong cash generation supports XPO's trajectory toward accelerating free cash flow generation. North American LTL performance was solid, with adjusted operating ratio improving 200 bps to 83.9% and 20% growth in adjusted operating income. Critically, tonnage per day turned positive at +0.1% vs. Q4 2025's -4.5% decline, marking an inflection point and suggesting early demand stabilization signs. Yield growth excluding fuel remained robust at 4.0%, supported by service improvements and AI-driven network optimization, while cash from operations grew 29% to $183M. In our view, XPO's insourcing strategy and operational leverage position the company well for continued margin expansion and cash flow growth.
$XPO
Research
Research Alert: Cigna: Mcr Improvement Supports Q1 Eps Beat, Guidance Raise
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CI reported Q1 2026 adjusted EPS of $7.79 (+16% Y/Y), beating the $7.61 consensus and prompting a $0.10 raise to annual EPS guidance. Total revenues rose 5% Y/Y to $68.5B, due to Evernorth Health Services' growth of 9% Y/Y to $58.4B, while Cigna Healthcare's revenues fell 21% Y/Y reflecting the Medicare business divestiture. The strong Evernorth performance, including 11% Y/Y growth in Pharmacy Benefit Services due to favorable drug mix and 6% Y/Y growth in Specialty and Care Services, supports the company's strategic pivot toward higher-margin services. Management maintained Medical Care Ratio guidance at 83.7%-84.7% for 2026, demonstrating continued cost discipline amid operational improvements. Operational efficiency improved with its SG&A expense ratio declining 100bps to 5.4%, while Cigna Healthcare pre-tax margins expanded 430bps to 13.2% and the Medical Care Ratio improved to 79.8% from 82.2%, primarily benefiting from the Medicare divestiture.
$CI
Research
JPMorgan Downgrades Kaiser Aluminum to Underweight From Neutral, Adjusts Price Target to $142 From $124
$KALU